【制药网 行业动态】 2025年,全球医药行业又迎来了新一轮研发管线调整,大批药物开发项目被终止,涉及肿瘤、代谢疾病、中枢神经系统(CNS)等多个领域,以及罗氏、辉瑞、强生、上海医药等众多国内外药企。近日,罗氏发布了2025年半年报,同时宣布砍掉7大研发管线,包括四项I期和三项III期临床研究。值得注意的是,其全球头个进入III期的TIGIT抑制剂——RG6058(tiragolumab)仅剩的...
Source Link【制药网 行业动态】 2025年,全球医药行业又迎来了新一轮研发管线调整,大批药物开发项目被终止,涉及肿瘤、代谢疾病、中枢神经系统(CNS)等多个领域,以及罗氏、辉瑞、强生、上海医药等众多国内外药企。近日,罗氏发布了2025年半年报,同时宣布砍掉7大研发管线,包括四项I期和三项III期临床研究。值得注意的是,其全球头个进入III期的TIGIT抑制剂——RG6058(tiragolumab)仅剩的...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.